1. Pink Sheet
  2. >>Compliance
  3. >>Marketing & Advertising

Off-Label Guidance Creates ‘Safe Harbor’ For Dissemination of Certain Info To HCPs

 
• By Brenda Sandburg

The FDA's revised draft guidance on scientific communications to health care providers about unapproved uses of products describes the studies that are likely to be scientifically sound and clinically relevant. The agency also gives recommendations on presenting off-label information on web pages and in exhibit halls.

Safe harbor
FDA guidance provides a safe harbor for manufacturer communications about unapproved uses of medical products. • Source: Shutterstock

After nearly a decade, the US Food and Drug Administration updated a draft guidance on off-label communications to convey what scientifically sound and clinically relevant information sponsors may share with healthcare providers and how best to present the information.

The guidance, “Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from Marketing & Advertising

More from Compliance

Big PBM Dominance Enabled By Affiliated Third Party Administrators Limiting Choices, FTC Told

 
• By Cathy Kelly

Complaints about TPAs offer an explanation of why self-funded employers continue to use the big three PBMs despite concerns about those relationships. Proposed solutions include banning retaliatory fees and data withholding.

EU 15% Tariff Deal Still Leaves Questions For Pharma On Possible Grace Period, Generic Exemption

 
• By Jessica Merrill

While the 15% rate is a substantial blow for pharmaceutical firms, the US-EU deal provides a framework for trade agreements with other countries that could see the industry avoiding higher tariffs elsewhere.

No Surprise Here: Foreign Drug Facilities Should Expect Surprise Inspections, US FDA Says

 
• By Sue Sutter

The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.